Floatz logo

Infigratinib

Bladder Cancer With FGFR3 Mutation or Fusion

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

122 Active assets in the Bladder Cancer With FGFR3 Mutation or Fusion cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
VINBLASTINE
University of Southern California
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Infigratinib is also rated in:

GBMDormant
CCC
Indicative ·
54 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →